查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609166

嗜中性白血球低下症治疗药物市场：依治疗方法、通路分类 - 全球预测 2025-2030

Neutropenia Treatment Market by Treatment (Antibiotics, Antifungals, Antivirals), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

嗜中性白血球低下症治疗市场2023年估值为143.9亿美元，预计2024年将达到150.8亿美元，复合年增长率为4.98%，2030年将达202亿美元，预计将达到3000万美元。

嗜中性白血球低下症，这是一个重要的问题，因为它会增加感染疾病的易感性。治疗包括使用 G-CSF 疗法、抗生素和抗真菌药物等药物，以增加接受化疗或患有骨髓疾病的患者的白血球数量并预防感染疾病。癌症和自体免疫疾病的盛行率不断上升，以及更容易感染这些疾病的老化人口不断增加，推动了对有效治疗的需求。治疗主要发生在医院、肿瘤中心和诊所，即时和持续的治疗至关重要。在最终用途领域，主要相关人员包括医疗保健提供者、患者和製药公司。成长要素包括生物技术的进步带来更有效的治疗、政府和私人对癌症研究的资助，以及有关嗜中性白血球低下症及其管理的认识计划的激增。新的商机包括开发长效药物配方和针对个别患者情况量身定制的个人化医疗方法。然而，市场开拓的限制包括高昂的治疗成本、严格的监管指南、药物的潜在副作用以及新兴市场缺乏早期诊断意识。同样具有挑战性的是嗜中性白血球低下症使得治疗通讯协定变得复杂。需要创新和研究的领域包括生物製药领域的进步，这将有助于开发具有成本效益的生物相似药和副作用较少的增强型 G-CSF 疗法。对非药物干预措施和整体患者管理方法的研究也有希望。深入研究精准医疗，利用巨量资料和人工智慧来预测患者对治疗的反应，可以进一步重塑市场动态。该市场竞争激烈，其特点是技术的快速进步以及研究机构和製药公司之间的合作，旨在提供创新的解决方案来满足未满足的医疗需求。

主要市场统计
基准年[2023] 143.9亿美元
预计年份 [2024] 150.8亿美元
预测年份 [2030] 202.3亿美元
复合年增长率（%） 4.98%

市场动态：揭示快速发展的嗜中性白血球低下症药物市场的关键市场洞察

供需的动态交互作用正在改变嗜中性白血球低下症药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 白血病盛行率增加
    • 癌症患者增加
    • 化疗导致嗜中性白血球低下症减少症增加
  • 市场限制因素
    • 治疗嗜中性白血球低下症症相关的高成本
  • 市场机会
    • 研发力道及开发新药快速加大
    • 嗜中性白血球低下症治疗药物尖端技术的发展
  • 市场挑战
    • 严格的产品核可规则和规定

波特五力：驾驭嗜中性白血球低下症药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对嗜中性白血球低下症药物市场的影响

外部宏观环境因素在塑造嗜中性白血球低下症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解嗜中性白血球低下症治疗药物市场的竞争状况

嗜中性白血球低下症治疗药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位嗜中性白血球低下症治疗市场供应商的绩效评估

FPNV 定位矩阵是评估嗜中性白血球低下症治疗药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了嗜中性白血球低下症治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，嗜中性白血球低下症治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 白血病发生率增加
      • 癌症发生率增加
      • 化疗引起的嗜中性白血球低下症减少症病例增加
    • 抑制因素
      • 治疗嗜中性白血球低下症症相关的高成本
    • 机会
      • 研发活动和开发新药迅速增加
      • 嗜中性白血球低下症治疗药物尖端技术的发展
    • 任务
      • 严格的产品核可规则和规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

嗜中性白血球低下症治疗药物市场（依治疗）

  • 抗生素
  • 抗真菌药物
  • 抗病毒药物
  • 集落刺激因子

嗜中性白血球低下症治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第八章北美和南美中性嗜中性白血球低下症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区嗜中性白血球低下症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲中性嗜中性白血球低下症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen, Inc.
  • BeyondSpring, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratory Ltd.
  • Enzychem Lifesciences Corporation
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Partner Therapeutics, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-FB6C9E793876

The Neutropenia Treatment Market was valued at USD 14.39 billion in 2023, expected to reach USD 15.08 billion in 2024, and is projected to grow at a CAGR of 4.98%, to USD 20.23 billion by 2030.

Neutropenia, characterized by an abnormally low count of neutrophils, is a significant concern due to its role in increasing susceptibility to infections. The treatment scope includes pharmaceuticals such as G-CSF therapies, antibiotics, and antifungal drugs, aiming to boost white blood cell count and prevent infections in patients undergoing chemotherapy or suffering from bone marrow disorders. The necessity for effective treatments is driven by the increasing prevalence of cancer and autoimmune diseases, and the rising geriatric population prone to these conditions. Applications primarily lie in hospitals, oncology centers, and clinics, where immediate and continuous treatment is imperative. On the end-use spectrum, major stakeholders include healthcare providers, patients, and pharmaceutical companies. Growth factors include advancements in biotechnology leading to more effective therapeutics, government and private funding for cancer research, and a surge in awareness programs regarding neutropenia and its management. Emerging opportunities include the development of long-acting drug formulations and personalized medicine approaches tailored to individual patient profiles. However, market limitations include the high cost of treatment, stringent regulatory guidelines, potential side effects of drugs, and lack of awareness regarding early diagnosis in developing regions. Challenges also entail the complexity of neutropenia's underlying causes which complicate treatment protocols. Areas ripe for innovation and research include biopharmaceutical advancements that allow developing cost-effective biosimilars and enhanced G-CSF therapies with fewer side effects. Research into non-pharmacological interventions and holistic patient management approaches also holds promise. A deeper exploration into precision medicine, leveraging big data and AI to predict patient responses to treatments, can further reshape market dynamics. The market is competitive, characterized by rapid technological advancements and collaborations between research institutions and pharmaceutical companies aimed at delivering innovative solutions to fulfill unmet medical needs.

KEY MARKET STATISTICS
Base Year [2023] USD 14.39 billion
Estimated Year [2024] USD 15.08 billion
Forecast Year [2030] USD 20.23 billion
CAGR (%) 4.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neutropenia Treatment Market

The Neutropenia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of leukemia
    • Rising incidences of cancer cases
    • Rising cases of chemotherapy-induced neutropenia
  • Market Restraints
    • High cost associated with the treatment of neutropenia
  • Market Opportunities
    • Surge in R&D Efforts and Development of New Drugs
    • Growth in advance technologies in Neutropenia treatment drugs
  • Market Challenges
    • Stringent rules & regulations for product approvals

Porter's Five Forces: A Strategic Tool for Navigating the Neutropenia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neutropenia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neutropenia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neutropenia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neutropenia Treatment Market

A detailed market share analysis in the Neutropenia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neutropenia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neutropenia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neutropenia Treatment Market

A strategic analysis of the Neutropenia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neutropenia Treatment Market, highlighting leading vendors and their innovative profiles. These include Amgen, Inc., BeyondSpring, Inc., Coherus BioSciences, Inc., Dr. Reddy's Laboratory Ltd., Enzychem Lifesciences Corporation, Intas Pharmaceuticals Ltd., Kyowa Kirin Co., Ltd., Ligand Pharmaceuticals, Inc., Novartis AG, Partner Therapeutics, Inc., Pfizer, Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Neutropenia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Antibiotics, Antifungals, Antivirals, and Colony-stimulating factor.
  • Based on Distribution Channel, market is studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of leukemia
      • 5.1.1.2. Rising incidences of cancer cases
      • 5.1.1.3. Rising cases of chemotherapy-induced neutropenia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of neutropenia
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in R&D Efforts and Development of New Drugs
      • 5.1.3.2. Growth in advance technologies in Neutropenia treatment drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent rules & regulations for product approvals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neutropenia Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Antibiotics
  • 6.3. Antifungals
  • 6.4. Antivirals
  • 6.5. Colony-stimulating factor

7. Neutropenia Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital pharmacies
  • 7.3. Online pharmacies
  • 7.4. Retail pharmacies

8. Americas Neutropenia Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Neutropenia Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Neutropenia Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen, Inc.
  • 2. BeyondSpring, Inc.
  • 3. Coherus BioSciences, Inc.
  • 4. Dr. Reddy's Laboratory Ltd.
  • 5. Enzychem Lifesciences Corporation
  • 6. Intas Pharmaceuticals Ltd.
  • 7. Kyowa Kirin Co., Ltd.
  • 8. Ligand Pharmaceuticals, Inc.
  • 9. Novartis AG
  • 10. Partner Therapeutics, Inc.
  • 11. Pfizer, Inc.
  • 12. Sanofi SA
  • 13. Spectrum Pharmaceuticals, Inc.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. NEUTROPENIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NEUTROPENIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUTROPENIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUTROPENIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023